Member Info for Rooba

It happens when an SP is going up or down rapidly and theres a mismatch between buys and sells.
So they stop the market for 5 minutes to try to achieve an average price. If the first one doesnt work, theres a 2nd one where a price will be determined.

So, to investors, it doesnt really mean anything other than a share price is rapidly going up or down.

Well said Sage.
I politely disagreed with ophidian on twitter months ago about tech transfer not being finished, and he just arrogantly, obnoxiously told me how knowledgeable he was and therefore he was correct - and then blocked me! I guess he’s incredibly insecure, as he can’t handle anybody disagreeing with him.

And he was wrong, of course, as he has been wildly wrong on a few of his ‘insights’. But if you predict enough things, eventually you’re going to get something right!

I have no idea whats going on with BAMS, but in my simple mind, I wonder how you can evaluate the degree of test accuracy, when your benchmark - the PCR - is flawed?
Do False positives from the PCR, of which there may be many, get counted as incorrect for BAMS if it correctly doesn’t identify them?
I have no idea how you then check without a fully accurate benchmark?
Could be part of the problem Condor have had, perhaps.

If the MMs deliberately bumped the price up at the end, any theories on why they would do it?
I cant think of any.

Thanks Hef’. Thats helpful.

I’ve got a small holding here and am looking to significantly increase it - the potential for the SP to massively increase looks excellent.
But, the director sells in december look significant and a possible red flag. Apologies if this has already been covered, but what are people’s views on the director deals? And am i missing something re the nature of the deals.
I’m still learning, so just looking for some help, thanks.

I thought the September updates managed expectations to news in November, and possibly late November.
Its uncomfortable waiting, but better to have that expectation than be disappointed every day.

I think they have been subtly playing down the S&S for a while, and the language has shifted from best in class to good enough.

But at the same time, i think governments and experts have also formed the view that rapid tests with less S&S is a lot better than current slow PCR testing.
So I’ll take ‘good enough’, as it will still sell as fast as they can make it

https://twitter.com/erictopol/status/1300156037954060288?s=21

Interesting article above covering testing, approvals and issues in the US.
It surprised me that the FDA have approved 150 tests, but almost all of them either poor accuracy, not trusted, or too expensive.
Looks like Avacta could fare well there, but getting noticed amongst all of the noise could be challenging. We may need Danaher to weigh in on Avacta’s behalf to help secure contracts.

Agree MrsKOB.
I think the way things are set up, the SP could fly on a headline news story as much as it could another substantive RNS

Its easy to see why investors are spooked by todays news (and lack of from Avacta), but there’s so much more of a market out there than our useless government. And I have a feeling the big money will be made from what Avacta sell in the USA.